HnRNP L and hnRNP LL antagonistically modulate PTB-mediated splicing suppression of CHRNA1 pre-mRNA

Mohammad Alinoor Rahman¹, Akio Masuda¹, Kenji Ohe¹, Mikako Ito¹, David O. Hutchinson²,³, Akila Mayeda⁴, Andrew G. Engel² & Kinji Ohno¹,²

¹Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan, ²Department of Neurology, Mayo Clinic, Rochester, Minnesota, U. S. A., ³Department of Neurology, Auckland City Hospital, Auckland, New Zealand, ⁴Division of Gene Expression Mechanism, Institute for Comprehensive Medical Science (ICMS), Fujita Health University, Toyoake, Aichi, Japan.

CHRNA1 gene, encoding the muscle nicotinic acetylcholine receptor alpha subunit, harbors an inframe exon P3A. Inclusion of exon P3A disables assembly of the acetylcholine receptor subunits. A single nucleotide mutation in exon P3A identified in congenital myasthenic syndrome causes exclusive inclusion of exon P3A. The mutation gains a de novo binding affinity for a splicing enhancing RNA-binding protein, hnRNP LL, and displaces binding of a splicing suppressing RNA-binding protein, hnRNP L. The hnRNP L binds to another splicing repressor PTB through the proline-rich region and promotes PTB binding to the polypyrimidine tract upstream of exon P3A, whereas hnRNP LL lacking the proline-rich region cannot bind to PTB. Interaction of hnRNP L with PTB inhibits association of U2AF65 and U1 snRNP with the upstream and downstream of P3A, respectively, which causes a defect in exon P3A definition. HnRNP L and hnRNP LL thus antagonistically modulate PTB-mediated splicing suppression of exon P3A.

In higher eukaryotes, alternative splicing enables precise regulations of gene expression with a limited number of genes. Recent reports reveal that ~95% of human genes undergo alternative splicing. Differential premRNA splicing is cooperatively coordinated by cis-elements comprised of exonic/intronic splicing enhancers/silencers (ESEs, ISEs, ESSs, and ISSs) and trans-factors that are tightly regulated in a tissue-specific and developmental stage-specific manner. The biogenesis of ribonucleoprotein complexes (RNPs) is thus coordinated with high fidelity to ensure that correct complements of RNA and proteins are present in the right cell at the right time. Mutations that impair formation of functional spliceosomes by disrupting the cis-elements, or by compromising RNA-binding or catalytic function of trans-factors can be deleterious to cells often cause human disease.

Congenital myasthenic syndromes (CMSs) arise from defects in genes coding for presynaptic, synaptic, and postsynaptic proteins at the neuromuscular junction (NMJ). Most CMSs are postsynaptic and most of these are caused by recessive mutations in the acetylcholine receptor (AChR) subunit genes. CHRNA1, encoding the AchR α subunit, harbors an alternatively spliced 75-nt inframe exon P3A between exons 3 and 4 (Fig. 1b). Only the transcript without exon P3A, P3A(−), encodes a functional α subunit that incorporates into functional AChR at the endplate. The transcript with exon P3A, P3A(+), harbors 25 extra amino acids and is inserted between codons 58 and 59 in the extracellular domain of the α subunit. Formation of a pentameric AChR starts with dimerization of the αd subunits and of the αe subunits via the extracellular domain of each subunit. Disruption of the extracellular domain by exon P3A is predicted to prevent formation of the αd and αe dimers. Exon P3A is alternatively spliced in humans, gorillas, chimpanzees, and orangutans, but not in rhesus monkeys, gibbons, mandrills, marmosets, dogs, and cats. In human skeletal muscle, the P3A(−) and P3A(+) transcripts are generated in a 1:1 ratio. The P3A(+) transcript is also expressed in the normal and in nonneoplastic thymus glands of myasthenic patients, but is absent or rarely expressed in thymomas. The functional significance of the P3A(+) transcript in muscle or in the thymus gland has not been elucidated to date. We previously reported that splicing regulators, hnRNP H1 and polypyrimidine tract-binding protein (PTB), bind to intron 3 upstream of exon P3A and suppress inclusion of exon P3A.

HnRNP L is an abundant nuclear protein that has been identified as a global splicing regulator. In addition to its important function in alternative splicing, hnRNP L also plays pivotal roles in polyadenylation, in export of
mRNA from genes lacking introns, in internal ribosome entry site (IRES)-mediated translation, and in mRNA stability. Recently, hnRNP L-like, also known as hnRNP LL, a closely related parologue of hnRNP L, has also been identified as a regulator of alternative splicing in activated T cells.

In a severely affected CMS patient, we have identified a critical mutation in exon P3A that causes exclusive inclusion of exon P3A in patient muscle. Here we demonstrate a fine modulating mechanism to promote either skipping or inclusion of exon P3A, which is mediated by similar, but antagonistic, hnRNP L and hnRNP LL factors. Remarkably, presence or absence of the proline-rich region (PRR) in hnRNP L and hnRNP LL, respectively, is a crucial determinant to trigger the following splicing repression system mediated by PTB.

Results
Missense and pseudo-missense mutations are detected in CMS. A 53-year-old man had severe myasthenic symptoms involving all voluntary muscles since birth, a decremental electromyographic response, and no circulating anti-AChR antibodies. He responded partially to combined treatment with anticholinesterase medications and 3,4-diaminopyridine. His parents were not consanguineous and he had no similarly affected relatives.

An intercostal muscle biopsy was obtained at age 41. On fluorescent microscopy, patient endplates (EPs) showed preserved expression of acetylcholinesterase and highly attenuated expression of AChR. On electron microscopy, the structural integrity of the junctional folds and nerve terminals was preserved but some postsynaptic regions were simpler than normal. Ultrastructural
localization of AChR with peroxidase-labeled α-bungarotoxin revealed marked decrease in the density and distribution of AChR on the junctional folds (Fig. 1a). The AChR index (defined as the length of the postsynaptic membrane reacting for AChR normalized for the length of the primary synaptic cleft) was reduced to ~29% of normal (Table 1). The amplitude of the miniature EP potentials (MEPPs) was reduced to ~23% of normal (Table 1). The number of quanta released by nerve impulse was normal. The safety margin of neuromuscular transmission in the patient is thus compromised by the AChR deficiency.

Direct sequencing of CHRNA1, CHRNB1, CHRNA, and CHRNA genes encoding the AChR α, β, δ, and ε subunits, respectively, revealed two heterozygous mutations in CHRNA1 (Fig. 1b). The G-to-A mutation at nucleotide position 1261 predicts a glycine-to-arginine substitution at codon 421 in the fourth transmembrane domain of the α subunit (P3A23). The amino acid, αG421A, was shared among all the human AChR subunits and it is also perfectly conserved in the α subunit across all vertebrate species (Fig. S1a and S1b). αG421A is not present in 200 normal alleles or in available SNP databases (dbSNP build 137, the 1000 Genomes Project, and the NHLBI ESP). When we transfected the AChR α subunit cDNA harboring G421R mutation along with wild-type β, δ, and ε subunit cDNAs into HEK293 cells, we found that the expression level of αG421R-AChR was reduced to ~15% (Fig. 1e), which underscored the pathogenicity of the αG421R mutation.

Because loss-of-function mutations in AChR subunit genes are generally recessive and individuals carrying a null mutation on a single allele are always asymptomatic, we looked for the second loss-of-function mutation in CHRNA1. We could not find any mutation except for the candidate G-to-A substitution at the 23rd nucleotide of the α3A exon (P3A23G>A), which predicts an arginine-to-histidine substitution at the 8th codon in exon P3A (Fig. 1b). The P3A23G>A mutation was not present in 200 normal alleles or in available SNP databases. We traced P3A23G>A and αG421R changes in family members, and found that these two mutations are heteroallelic and recessive (Fig. 1c). We first assumed that P3A23G>A was a rare polymorphism, because a wild-type αA did not rescue the cell surface expression (Fig. 1e). Because an exhaustive search for other mutations in the α subunit, including single allele analysis by the ‘conversion’ method, detected no additional mutation, we examined the effects of P3A23G>A on pre-mRNA splicing.

**Table 1 | Morphometric and electrophysiological studies of endplates of the patient**

|       | Patient | Controls |
|-------|---------|----------|
| AChR index | 0.87 ± 0.01 (27) | 3.01 ± 0.11 (85) |
| EPP quantal content | 27 ± 8 (18) | 31 ± 1 |
| MEPP amplitude (μV) | 20.3 ± 0.015 (16) | 1.00 ± 0.025 (16) |

Values represent mean ± standard error (SE). Numbers in parenthesis indicate number of endplates (EP).

**αP3A23G>A disrupts a putative exonic splicing silencer.** We constructed a minigene harboring exons 2 to 4 of CHRNA1 (Fig. 2a) in the pRbg4 mammalian expression vector to dissect the cis-element of splicing. We transfected COS cells with the wild-type and mutant minigenes and confirmed that the minigenes recapitulated the effect of the identified mutation on splicing (Fig. 2a). To examine whether the identified mutation disrupts an ESE or generates an ESE, we introduced five artificial mutations between nucleotide positions 22 and 24 (Fig. 2a). All mutants enhanced incorporation of exon P3A, indicating that G at position 23 as well as its flanking nucleotides constitute an ESS and αP3A23G>A mutation disrupts it.

We also inserted exon P3A and its flanking introns between the two proprietary constitutive exons of the modified exon-trapping vector pSPL3 (Fig. 2b) to test whether the mutation can recapitulate the aberrant splicing in a heterologous context. The αP3A23G>A in pSPL3 indeed reiterated the enhanced recognition of exon P3A in COS and SH-SY5Y cells (Fig. 2b), which suggested that exon P3A and its flanking intronic sequences are sufficient to regulate inclusion or skipping of exon P3A. We also compared splicing efficiencies of the wild-type P3A construct in pSPL3 in COS, SH-SY5Y, HEK293, and HeLa cells (Fig. 2b, and data not shown), and found that the P3A(−) and P3A(+) transcripts were expressed at a 1:1 ratio in SH-SY5Y cells, as in human skeletal muscle. We thus obtained a faithful splicing system with SH-SY5Y cells and pSPL3 constructs for further mechanistic analyses.

**αP3A23G>A disrupts binding of hnRNPL while gains binding of hnRNPL.** Having identified the critical cis-element of splicing, we next sought for a trans-factor responsible for regulating inclusion or skipping of exon P3A. RNA affinity purification of the nuclear extract prepared from SH-SY5Y cells with the wild-type P3A RNA probe yielded a ~70 kDa protein (Fig. 3a). Analysis of the excised band by mass spectrometry revealed 26 unique peptides that matched to hnRNPL (the Mascot score of 343; significance threshold, p < 0.05). Immunoblotting demonstrated that the protein bound to the wild-type P3A exon was indeed hnRNPL with a predicted molecular weight of ~68 kDa (Fig. 3b, lane 1). As expected, the αP3A23G>A-mutated probe diminished the binding affinity for hnRNPL (Fig. 3b, lane 2). We further examined binding of other candidate splicing factors; hnRNPL, hnRNPK, hnRNP J, SRFS1 (formerly SF2/ASF), SRFS2 (formerly SC35), SRFS5 (formerly SRp40), and SRFS6 (formerly SRp55) (Fig. 3b and Fig. S2b). We found that none bound to the wild-type probe, but unexpectedly the mutation de novo gained binding for hnRNPL (Fig. 3b, lane 2). We also resolved the RNA affinity-purified proteins bound to the mutant probe by mass spectrometry and identified hnRNPL with the Mascot score of 124 (significance threshold, p < 0.05).

Overlapping binding motifs are responsible for a competitive binding of hnRNPL and hnRNPL. Previous reports suggest that both hnRNPL and hnRNPL preferentially bind to CA-repeat or C/ A-rich sequences. In vitro SELEX studies of hnRNPL demonstrated that CACA and CACG sequences confer low-affinity and that CACG and CACC sequences confer low-affinity binding motifs for hnRNPL. Although no SELEX data are available for hnRNPL, hnRNPL prefers to bind to CACC sequence of the CD45 transcript. The wild-type exon P3A carries the low-affinity binding CACC site for hnRNPL (Fig. 3c). The αP3A23G>A mutation rather changes the low-affinity CACC site to a high-affinity CACA site. In addition, this mutation acquires a low-affinity CACC site for hnRNPL, which also serves as a de novo binding site for hnRNPL. Accordingly, this mutation disrupts the native CACC motif for hnRNPL and introduces two novel
overlapping CACA and CACC motifs for hnRNP L as well as a novel CACC motif for hnRNP LL. Affinity-purification experiments, however, showed that the mutation abolishes binding of hnRNP L. We thus dissected the molecular basis of the loss of hnRNP L-binding.

Deletion of nucleotides 20 and 21 (Δ20–21) from the mutant sequence abrogates the high affinity CACA motif for hnRNP L but retains the CACC motif for hnRNPs L and LL (Fig. 3c). Affinity purification of nuclear extract from SH-SY5Y cells with Δ20–21 probe showed loss of hnRNP L and gain of hnRNP LL binding (Fig. 3c, lane 1). Similarly, deletion of nucleotides 24 to 26 (Δ24–26) from the mutant sequence generates a high affinity CACACA motif for hnRNP L, but abrogates the CACC motif for hnRNP LL. As predicted, Δ24–26 probe gave rise to binding of hnRNP L (lane 2).

Additionally, deletion of nucleotides 20 to 26 (Δ20–26) from the mutant sequence abrogates all affinity motifs for hnRNPs L and LL, and indeed it did not bind to either hnRNP L or LL (lane 3). This suggests that hnRNPs L and LL compete for binding to the overlapping site of the mutated sequence in exon P3A, and consequently hnRNP LL wins the competition.

To further confirm the competitive binding of hnRNPs L and LL, we depleted hnRNP L or LL from nuclear extract of SH-SY5Y cells (Fig. S2c) and performed RNA affinity purification assays. As we predicted, depletion of hnRNP LL restored binding of hnRNP L to the mutant probe (Fig. 3d, lane 6), which underscored a notion that hnRNP LL competes with hnRNP L for binding to the mutant probe.

HnRNP L silences and hnRNP LL enhances inclusion of exon P3A.

We next examined the effects of hnRNPs L and LL on splicing of exon P3A by siRNA-mediated downregulation of hnRNPs L and LL in SH-SY5Y cells (Fig. 3e). Downregulation of hnRNP L induced inclusion of exon P3A in the wild-type minigene (Fig. 3e, lane 3), whereas downregulation of hnRNP LL caused skipping of exon P3A in the mutant minigene (lane 6), indicating that hnRNPs L and LL function as splicing silencer and enhancer, respectively. Expression of siRNA-resistant hnRNPs L (si-res L) and LL (si-res LL) along with siRNA in SH-SY5Y cells negated possible off-target effects of siRNAs (Fig. S3a).

We next confirmed that hnRNPs L and LL indeed work on the identified cis-element and not on the other sites. To this end, we tethered hnRNPs L and LL to the target using the bacteriophage MS2 coat protein. We prepared an effector construct expressing MS2-tagged hnRNP L or LL protein (MS2-L and MS2-LL, respectively), and the target minigene construct (pSPL3-MS2) containing the MS2-binding site, which was substituted for the native target site. As we expected, tethering of hnRNP L to the target promoted skipping of exon P3A (Fig. 3f, lane 5), whereas tethering of hnRNP LL induced inclusion of exon P3A (lane 6). Lack of splicing modulating effects of hnRNPs L and LL without MS2-tag indicates that neither hnRNP L nor LL works on the other sites (Fig. 3f, lanes 3 and 4). We also confirmed that MS2-fused hnRNPs L and LL had no effect on a minigene lacking the MS2-binding site (pSPL3-nonMS2) (Fig. S3b).

Thus, hnRNP L and hnRNP LL exert silencing and enhancing activities on the identified target site.

The proline-rich region of hnRNP L is essential for skipping of exon P3A.

We next dissected functional domains of hnRNPs L and LL that dictate skipping and inclusion of exon P3A, respectively. HnRNP L (589 amino acids; accession number, NP_001524) and hnRNP LL (542 amino acids; NP_612403) are paralogues of similar size. They share an overall amino acid identity of 58%, and contain three highly conserved RNA-recognition motifs (RRMs) (Fig. 4a)29. HnRNP LL, however, differs in two domains from hnRNP L: its N-terminal glycine-rich region (GRR) is less prominent, and it lacks the proline-rich region (PRR) (Fig. 4a). We thus postulated that one or both of these distinct regions determine the splicing suppressing activity of hnRNP L. To prove this, we

Figure 2 | Construction of minigenes and splicing assays. (a) Structure of CHRNA1 gene and pRBG4 minigene. A 589-bp segment (broken line) in intron 3 is deleted in pRBG4 minigene. The patient’s mutation and five artificial mutations are introduced into pRBG4 minigene. Ratios of exon P3A skipping are quantified by real-time RT-PCR of COS cells transfected with pRBG4 minigenes. (b) pSPL3 minigene harboring CHRNA1 exon P3A and flanking introns. Arrowheads point to the boundaries of CHRNA1 and pSPL3 vector. Ratios of exon skipping are analyzed by RT-PCR of COS cells and SH-SY5Y cells transfected with pSPL3 minigenes. Bars and lines represent mean and standard deviation (SD), respectively, of three independent experiments for both (a) and (b).
constructed a series of deletion mutants of hnRNP L and introduced them into SH-SY5Y cells along with the target pSPL3-MS2 substrate carrying the MS2-binding site. To prevent the possible effect of each deletion on a nuclear-localization signal, we introduced the nuclear-localization signal sequence of the SV40 large T-antigen at the N-terminal end of each construct. We found that deletion of GRR from the MS2-hnRNP L fusion construct (MS2-L-DGRR) had no effect on skipping of P3A exon (Fig. 4b, lane 3), whereas deletion of PRR (MS2-L-DPRR) caused inclusion of P3A exon (lane 4). Further deletions including RRM2 (MS2-L-DPRR-D2-R2-RRM2) and RRM3 (MS2-L-DPRR-D2-R2-RRM3) completely lost the splicing effects of hnRNP L (Fig. 4b, lanes 5 and 6). In contrast, artificial insertion of PRR into hnRNP L (MS2-L-PRR) transformed the exon P3A inclusion activity of hnRNP L to the exon P3A skipping activity (Fig. 4b, lanes 7 and 8). We conclude that PRR is responsible for the exon skipping activity of hnRNP L, and the exon inclusion activity of hnRNP LL is attributed to the lack of PRR.

HnRNP L and PTB cooperatively prevent inclusion of exon P3A. We next asked how PRR of hnRNP L confers exon skipping activity. We previously reported that PTB binds to polypyrimidine tract (PPT) of intron 3 and suppresses inclusion of exon P3A (Fig. 4c)16. Although direct binding of hnRNP L and PTB has been previously reported30, its mechanistic basis on splicing was not yet resolved. Based on our data, we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon P3A. We thus examined the role of PRR of hnRNP L on the interaction with PTB. Histidine-tagged hnRNP L (His-L), its PRR-deleted variant (His-L-DPRR), histidine-tagged hnRNP LL (His-LL), and its PRR-inserted variant (His-LL-PRR) were expressed in SH-SY5Y cells, and they were immunoprecipitated with anti-histidine antibody in the presence of RNase. Immunoblotting revealed that PTB was precipitated with His-L but not with His-LL-PRR (Fig. 4e). On the other hand, PTB was not precipitated with hnRNP LL (His-LL) but was detected with His-LL-PRR (Fig. 4e). These results indicate that PRR of hnRNP L enables hnRNP L to interact with PTB.

We next examined whether the splicing suppressive effects of PTB and hnRNP L were additive or cooperative. Enhanced inclusion of exon P3A by knocking down of both hnRNP L (siL) and PTB (siPTB)
Figure 4 | HnRNP L interacts with PTB through proline-rich region (PRR) to synergistically repress inclusion of exon P3A. (a) Schematic domain-structures of hnRNPs L and LL and their mutant derivatives. Interaction of each protein product with PTB is indicated on right according to the results from panels (d) and (e). RRM, GRR and ND indicate RNA recognition motif, glycine-rich region and not detected respectively. (b) RT-PCR of pSPL3-MS2 products after the indicated MS2-tagged trans-acting effectors are introduced into SH-SY5Y cells. Bars and lines represent mean and SD, respectively, of three independent experiments. Immunoblotting shows expression of effectors in the nuclear lysate of SH-SY5Y cells. (c) Schematic binding sites of hnRNP L and PTB in exon P3A and upstream PPT (YYYY) respectively. (d) Interaction of PTB with His-tagged hnRNP L and its indicated mutant. Nuclear extract of transfected SH-SY5Y cells is immunoprecipitated with anti-His antibody and assayed for interaction with endogenous PTB by immunoblotting (IB). Open arrowheads point to IgG heavy chain (HC) that was non-specifically precipitated. (e) Interaction of PTB with His-tagged hnRNP LL and its indicated mutant. See (d) for the procedures and other labels.
Figure 5 | Skipping of exon P3A is promoted by impairing the formation of exon-defined E (EDE) complex in the wild-type pre-mRNA. (a) Time-course data obtained from in vitro splicing of the 32P-labeled pre-mRNAs from E3P3A (wt and mut) and P3AE4 (wt and mut) minigenes. The splicing products are shown schematically on the right. The spliced mRNA (asterisk) is increased in E3P3A-mut compared to E3P3A-wt. Although intron lariats are apparently increased in E3P3A-wt, the intron lariat and high molecular weight RNAs are not clearly resolved for E3P3A, and the increase of the intron lariats cannot be precisely estimated. Poor resolution of splicing products of E3P3A compared to P3AE4 is likely due to binding of a splicing repressing PTB. (b) Time-course analysis of early exon-defined spliceosome (EDE complex) that assembles across the P3A exon of 32P-labeled substrates (iP3Ai-wt and iP3A-mut) in the absence of ATP. Native agarose gel electrophoresis resolves the indicated nonspecific complex H (H) and the exon-defined E complex (EDE). (c) Schematic structures of MS2-attached wild-type (wt) and mutant (mut) substrates used for isolation of EDE complex. Immunoblotting (IB) and RT-PCR analyses of purified E complex assembled on indicated substrates. PTB was likely bound to a CUCUCUCU sequence in intron 1 of β-globin-MS2 pre-mRNA.
was similar to that observed by siL or siPTB alone (Fig. S4), which suggested that PTB and hnRNP L cooperatively drive skipping of exon P3A with no additive effect.

**HnRNP L–PTB interaction impairs the exon-definition E complex formation to promote skipping of exon P3A.** To further delineate the precise mechanism by which hnRNP L–PTB interaction causes skipping of exon P3A, we employed an in vitro splicing assay using a HeLa cell nuclear extract. Since PTB binds to PPT upstream of exon P3A and hnRNP L binds to exon P3A, we made two sets of splicing substrates, both of which carried either wild-type (wt) or mutant (mut) sequence. The structure of one set was “exon 3-intron 3-exon P3A” (E3P3A-wt and E3P3A-mut), and that of the other was “exon P3A-intron P3A-exon 4” (P3AE4-wt and P3AE4-mut). This substrate system could inform us on whether the hnRNP L–PTB interaction affects the 3’ or 5’ splice site of exon P3A. E3P3A-mut was spliced more efficiently than E3P3A-wt, whereas P3AE4-mut was spliced as efficiently as P3AE4-wt (Fig. 5a). These results indicate that the binding of hnRNP L to wild-type exon P3A stabilizes association of PTB to the upstream PPT. The stabilized association precludes binding of U2AF65 to the PPT and also binding of U1 snRNP to the downstream 5’ splice site. The impaired definition of exon P3A thus gives rise to exon P3A-skipped mRNA (Fig. 6a). In the mutant CHRNA1 pre-mRNA, the binding of hnRNP LL to the mutant sequence in exon P3A excludes the competing hnRNP L, allowing association of U2AF65 and U1 snRNP to the upstream PPT and downstream 5’ splice site, respectively; this, in turn, leads to the exon P3A definition that favors formation of the exon P3A-included species of mRNA (Fig. 6b).

**Discussion**

Exonic and intronic mutations that affect cis-acting splicing elements have been reported in many diseases. More than 16–20% of missense mutations of the human mismatch-repair genes hMSH2 and hMLH1 are predicted to disrupt exonic splicing enhancers, which modulate splicing of transcripts containing mutated exons. However, splicing mutations in nonfunctional exons have not been well studied because they are often considered rare polymorphisms. We here identified a pathogenic splicing mutation (nPSA23^G>A) in a nonfunctional exon P3A of CHRNA1 in a CMS patient. Thus our study underscores the importance of including nonfunctional exons in mutation analysis.

We confirmed exclusive inclusion of exon P3A in the patient’s muscle. Due to lack of available human skeletal muscle cell lines, we used the SH-SY5Y human neuroblastoma cell line because the splicing patterns of our minigenes in SH-SY5Y cells were similar to those in the patient. HnRNP L is expressed ubiquitously and abundantly in almost all cell types, whereas prominent expression of hnRNP LL has been reported only in lymphoid cells, activated T-cells, and testes. The EST profile in the NCBI UniGene database shows that hnRNPs L and LL are similarly expressed in human skeletal muscle. The equivalent expression levels of hnRNPs L and LL in SH-SY5Y cells enabled us to recapitulate the splicing patterns we observed in patient muscle.

In CHRNA1 exon P3A, the mutation still retains suboptimal binding motifs of hnRNP L but hnRNP LL competitively prevents binding of hnRNP L. Specific binding motifs of hnRNP L on CD45 exons 4, 5, and 6 were found and those of hnRNP LL on CD45 exons 4 and 6 have previously been analyzed. In contrast to the event in CHRNA1, hnRNPs L and LL bind noncompetitively to adjacent sites within a single silencer element on CD45 exon 4 and suppress splicing cooperatively. Competitive binding of antagonizing splicing trans-factors to an identical exon has been observed in SMN1 and SMN2 pre-mRNAs. SMN1 and SMN2 genes are highly homologous paralogues differing only at 6th nucleotide of exon 7 in T vs C, respectively. Inclusion of SMN1 exon 7 is enhanced by SRSF1. The T-to-C substitution in SMN2 abolishes binding of splicing-stimulating SRSF1, and enhances binding of a splicing-suppressing hnRNP A1. In contrast to hnRNPs L and LL in the case of CHRNA1 pre-mRNA, SRSF1 and hnRNP A1 do not compete for binding to the overlapping target site. Competitive binding of two antagonizing

---

**Figure 6 | Model of pathogenic mutation (nPSA23^G>A)-induced aberrant exon P3A inclusion that is antagonistically regulated by hnRNPs L and LL.** Early spliceosome complex formation on CHRNA1 pre-mRNA with alternative exon P3A are schematically shown. Large letters indicate functional binding of splicing factors, whereas small letters represent compromised binding of splicing factors. The sequence of point mutation in exon P3A (nPSA23^G>A) is underlined. (a) HnRNP L (L) binds to wild-type exon P3A and interacts with PTB through the proline-rich region (PRR), which stabilizes PTB binding to the upstream PPT (YYYY). The hnRNP L–PTB interaction prevents association of U2AF65 (65) to PTB and U1 snRNP (U1) to the 5’ splice site. The formation of exon-defined E (EDE) complex is thus impaired, which leads to skipping of exon P3A. (b) The nPSA23^G>A-mutation switches binding of hnRNP L to hnRNP LL (LL). Lack of PRR in hnRNP LL fails to stabilize PTB binding to the upstream PPT, which allows binding of U1 snRNP (U1) and U2AF65 (65) on pre-mRNA. The formation of the exon-defined E (EDE) complex facilitates inclusion of exon P3A.
splicing *trans*-factors to the same target is thus unique to *CHRNA1* exon P3A.

The splicing repressor activity of PTB has been extensively characterized\(^{13-20}\). Splicing repressor activity of hnRNP L has been extensively investigated in CD45 pre-mRNA\(^{16,61,62}\). We here report a novel mechanism of PTB-mediated inhibition of exon-defined spliceosome formation, in which hnRNP L facilitates binding of PTB to the upstream PPT that suppresses subsequent association of U2AF\(^{25}\) and U1 snRNP in the exon-defined E complex. Another example of PTB-hnRNP association has been reported for PKM encoding pyruvate-kinase-M, where PTB and hnRNPs A1/A2 cooperate in excluding exon 9 to increase lactate production in cancer cells\(^{25}\). Together, hnRNP proteins appear to be functional partners of PTB which binds to upstream PPT to inhibit E complex formation and leads to the subsequent splicing suppression.

We have identified unique PRR in hnRNP L that plays an essential role in binding of PTB to PPT to suppress splicing activity. Interestingly, a recent report showed that a PRR-containing linker domain of hnRNP L binds to hnRNPs A1 in an RNA-dependent manner and binding of both molecules to CD45 exon 4 causes skipping of exon 4\(^{26}\). Similarly, a specific peptide motif and adjacent PRR of Raver1 are essential for PTB-mediated splicing repressor activity\(^{27}\). Of Raver1 are essential for PTB-mediated splicing repressor activity of hnRNP L has been extensively characterized\(^{39-42}\). Splicing repressor activity of hnRNP L has been extensively characterized\(^{39-42}\). We here report a novel mechanism of PTB-mediated inhibition of exon-defined spliceosome formation, in which hnRNP L facilitates binding of PTB to the upstream PPT that suppresses subsequent association of U2AF\(^{25}\) and U1 snRNP in the exon-defined E complex. Another example of PTB-hnRNP association has been reported for PKM encoding pyruvate-kinase-M, where PTB and hnRNPs A1/A2 cooperate in excluding exon 9 to increase lactate production in cancer cells\(^{25}\). Together, hnRNP proteins appear to be functional partners of PTB which binds to upstream PPT to inhibit E complex formation and leads to the subsequent splicing suppression.

In contrast to hnRNP L, the molecular mechanisms of splicing-modulating activity of hnRNP LL has not been extensively elucidated. A recent study reported the variations of domain structure between hnRNP L and LL, which exhibit functional alterations\(^{46}\). Here, we first prove that lack of PRR accounts for lack of interaction of hnRNP LL with PTB, which destabilizes PTB-binding to the upstream PPT. This, however, is unlikely to be an exclusive splicing-enhancing mechanism of hnRNP LL because tethering of hnRNP LL to exon P3A decreased the ratio of exon-skipped transcript further than a null-tethered control (from 18.4% to 9.8% in Fig. 3f, lanes 1 and 6). Although the effect of hnRNP LL on *CHRNA1* exon P3A is not as conspicuous as that of hnRNP L, hnRNP LL is likely to have a yet unidentified positive stimulatory effect on splicing.

An important question is why humans and great apes acquired alternative splicing of *CHRNA1* transcripts in the course of evolution. Alternative exons have evolved by exonization of retroposed mobile elements, whereby new exons are generated following changes in noncoding regions of a gene\(^{46-49}\). Exon P3A and its flanking intronic region have indeed arisen from exonization of the retropositional element MIR\(^{50}\). Moreover, exonization of MIR leading to the generation of exon P3A is likely to have a yet unidentified positive stimulatory effect on splicing.

**RNA affinity purification assay and mass spectrometry.** Biotinylated RNAs were synthesized in *vitro*, and RNA affinity purification assay was performed with a nuclear extract of SH-SYSY cells as previously\(^{20}\). The purified proteins were fractionated on a 10% SDS-polyacrylamide gel and stained with Coomassie blue or analyzed by immunoblotting as we previously described\(^{20}\). A Coomassie blue-stained band was excised from the gel and was digested in-gel by Trypsin Gold (Promega) according to the manufacturer’s protocols. For in-solution digestion, the RNA-bound proteins were eluted in elution buffer (0.1 M glycine with 2 M urea, pH 2.9) and digested by Trypsin Gold according to the manufacturer’s recommendations. Nanoelectrospray tandem mass analysis was performed using an LCQ Advantage Mass Spectrometry System (Thermo Finnigan). Multiple MS/MS spectra were analyzed by the Mascot program version 2.1.4 (Matrix Science).

**Depletion of hnRNP L and hnRNP LL from nuclear extract.** Antibody mediated depletion of hnRNP L and hnRNP LL from SH-SYSY cell nuclear extract was performed using Protein G HP spin trap (GE Healthcare) according to the manufacturer’s instructions.

**siRNA knockdown and minigene splicing.** siRNAs were synthesized to downregulate hnRNP L, hnRNP LL, and PTB by Sigma Genosys: 5′-GAAUGG AGUUCAGGCGAUGTT-3′ for human hnRNP L\(^{11}\), 5′-AGUGGCAAGGUAUUGG UAUATT-3′ for human hnRNP LL\(^{17}\) and 5′-GCCCUUUUAUCUUUCUGGT-3′ for human PTB\(^{16}\). The control siRNA was AllStar Negative Control siRNA (1027281) by Qiagen. For the siRNA rescue assay, we purchased the human cDNA clones for *HBUL1* (clone ID 6714088) and *HNRPLL* (clone ID 3502860) from Open Biosystems. We cloned each cDNA in pcDNA3.1/V5-His TOPO and introduced four artificial MS2 coat protein target sites into the 3′ untranslated region (UTR) of each construct. We then performed a tethered function assay using the Nuclear Complex Co-IP kit.
indicated time at 30

SCIENTIFIC

Cruz Biotechnology), anti-PTB (sc-16547, Santa Cruz Biotechnology), and anti-GAPDH (Sigma-Aldrich), anti-

32307, Santa Cruz Biotechnology, Inc.), anti-His-tag (D293-1, Medical & Biological

and analyzed them by immunoblotting using the antibody against PTB.

3.5 mM MgCl2. RNA was extracted with phenol, precipitated with ethanol, and

melting-point agarose (Invitrogen) submarine gel electrophoresis at 4

CGCAGTCC-3

C.

Engel, A. G., Ohno, K. & Sine, S. M. Sleuthing molecular targets for neurological

3. Licatalosi, D. D. & Darnell, R. B. Splicing regulation in neurologic disease.

1. Pan, Q., Shai, O., Lee, L. J., Frey, B. J. & Blencowe, B. J. Deep surveying of

alternative splicing complexity in the human transcriptome by high-throughput

4. Kreienkamp, H. J., Maeda, R. K., Sine, S. M. & Taylor, P. Intersubunit contacts

6. Beeson, D., Morris, A., Vincent, A. & Newsom-Davis, J. The human muscle

52

J Neurosci

52

Genome Res

5

RNA 14, 284–296 (2006).

14. Willich, A. et al. Association of acetylcholine receptor alpha-subunit gene

expression in mixed thymoma with myasthenia gravis. Neurology 52, 1460–1466

1999).

Masuda, A. et al. hnRNP H enhances skipping of a nonfunctional exon P3A in

CHRNA1 and a mutation disrupting its binding causes congenital myasthenic

syndrome. Hum Mol Genet 17, 4022–4035 (2008).

Bian, Y. et al. Tannic acid facilitates expression of the polyU-rich trinucleotide

and alleviates deleterious inclusion of CHRNA1 exon P3A due to an

hnRNP H-disrupting mutation in congenital myasthenic syndrome.

Hum Mol Genet 18, 1229–1237 (2009).

12. Gupta, S. et al. hnRNP G interacts with the polyU-rich trinucleotide

and alleviates deleterious inclusion of CHRNA1 exon P3A due to an

hnRNP H-disrupting mutation in congenital myasthenic syndrome.

Hum Mol Genet 18, 1229–1237 (2009).

Aniversaria, RNA 14, 284–296 (2006).

13. Andreotta, F. et al. Acetylcholine receptor alpha-subunit isoforms are
differentially expressed in thymuses from myasthenic patients. Am J Pathol 150,

341–348 (1997).

In vitro splicing and spliceosomal E complex assays. In vitro splicing was performed as
described previously40 with minor modifications. 40-I labeled pre-mRNA (~20 fmol) was incubated with 3.5 µl of HeLa cell nuclear extract (GibBiotec) for the indicated time at 30°C for P3AE4-wt/mut. As splicing efficiencies of E3P3A-wt/mut

were poor at standard temperature of 30°C, we improved the efficiencies by pre-

incubating the reaction mixture for 15 min at 37°C. The reaction mixture of 12.5 µl contained 3 mM ATP, 20 mM creatine phosphate, 20 mM HEPES-NaOH (pH 7.3),

and 3.5 mM MgCl2. RNA was extracted with phenol, precipitated with ethanol, and

fractionated by denaturing 7% or 10% PAGE. Spliceosomal E complex assay was

performed as previously described40 except of the use of 1× Tris-glycine and 2% low-

melting-point agarose (Invitrogen) submarine gel electrophoresis at 4°C.

MS2-affinity isolation of spliceosomal E complex of exon P3A. One pmol of the

RNA probe (MS2-human β-globin, MS2-P3A31-wt, or MS2-P3A31-mut) was incubated with 20-fold molar excess of MS2-MBP fusion protein40, prior to mixing with HeLa nuclear extract. Fifty µl of HeLa nuclear extract was preincubated with 10 µl (bead volume) of amylase resin (New England Biobads) overnight at 4°C. The purified HeLa nuclear extract was incubated at 37°C for 30 min with a mixture of the RNA probe and the MS2-MBP fusion protein at final concentrations of 60 µM mMs2 and 25% of HeLa nuclear extract. Ten µl (bead volume) of amylase resin was added and rotated at 4°C for 30 min. The resin was washed four times with wash buffer (20 mM HEPES pH 8.0, 150 mM KCl, and 0.5% Triton X-100), and finally eluted with 10 mM maltose solution and subjected to SDS-PAGE and immunoblot analyses.

To detect U1 snRNA, total RNA was purified from the isolated RNA affinity-isolated spliceosomal E complex using TRI Reagent (Sigma-Aldrich) according to the manufacturer’s instructions. After making cDNA with ReverTra Ace (Toyobo), U1 snRNA was detected using primers: 5’-GGGGAGATCCATCACTCGAGGAGGAGATACCC-3’ and 5’-GGGGATCCATGATCTTACCTGGCAGGGGAGATACC-3’.
45. Clower, C. V. et al. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A 107, 1894–1899 (2010).
46. Chiou, N. T., Shankarling, G. & Lynch, K. W. hnRNP L and hnRNP A1 induce extended U1 snRNA interactions with an exon to repress spliceosome assembly. Mol Cell 49, 972–982 (2013).
47. Rideau, A. P. et al. A peptide motif in Raver1 mediates splicing repression by interaction with the PTB RRM2 domain. Nat Struct Mol Biol 13, 839–848 (2006).
48. Shankarling, G. & Lynch, K. W. Minimal functional domains of paralogues hnRNP L and hnRNP LL exhibit mechanistic differences in exonic splicing repression. Biochem J 453, 271–279 (2013).
49. Sorek, R., Ast, G. & Graur, D. Alu-containing exons are alternatively spliced. Genome Res 12, 1060–1067 (2002).
50. Krull, M., Petrusma, M., Makalowski, W., Brosius, J. & Schmitz, J. Functional persistence of exonized mammalian-wide interspersed repeat elements (MIRs). Genome Res 17, 1139–1145 (2007).
51. Duclert, A., Savatier, N., Schaeffer, L. & Changeux, J. P. Identification of an element crucial for the sub-synaptic expression of the acetylcholine receptor epsilon-subunit gene. J Biol Chem 271, 17433–17438 (1996).
52. Koike, S., Schaeffer, L. & Changeux, J. P. Identification of a DNA element determining synaptic expression of the mouse acetylcholine receptor delta-subunit gene. Proc Natl Acad Sci U S A 92, 10624–10628 (1995).
53. Hutchinson, D. O. et al. Congenital endplate acetylcholinesterase deficiency. Brain 116 (Pt 3), 633–653 (1993).
54. Engel, A. G., Nagel, A., Walls, T. J., Harper, C. M. & Waisburg, H. A. Congenital myasthenic syndromes: I. Deficiency and short open-time of the acetylcholine receptor epsilon subunit. Ann Neurol 40, 810–817 (1996).
55. Engel, A. G., Ohno, K., Bouzat, C., Sine, S. M. & Griggs, R. C. End plate acetylcholine receptor deficiency due to nonsense mutations in the epsilon subunit. Neurology 27, 307–315 (1977).
56. Uchitel, O. et al. Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit. Neuron 17, 157–170 (1996).
57. Das, R., Zhou, Z. & Reed, R. Functional association of U2 snRNP with the ATP-independent spliceosomal complex E. Mol Cell 5, 779–787 (2000).

Acknowledgements
We are grateful to Robin Reed (Harvard Medical School, Boston, MA) for kindly providing MS2-MBP fusion protein and to Kentaro Taki (Nagoya University) for his technical assistance on the mass spectrometry analysis. This work was supported by Grants-in-Aid from the MEXT and MHLW of Japan to AM1, KeO, MI, AM4, and KiO; and by NIH Research Grant NS6277 from the NINDS and by Research Grant from the MDA to AGE.

Author contributions
A.G.E. and Ki.O. conceived the project. M.A.R., A.M.,1 Ke.O. and M.I. designed experiments; M.A.R. performed most of the experiments; Ke.O., D.O.H., Ke.O. contributed to genetic studies, electrophysiological studies, and in vitro spliceosome studies, respectively. M.A.R., Ke.O., A.M.,4 A.G.E. and Ki.O. wrote the paper.

Additional information
Supplementary information accompanies this paper at http://www.nature.com/scientificreports

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Rahman, M. A. et al. HnRNP L and hnRNP LL antagonistically modulate PTB-mediated splicing suppression of CHRNA1 pre-mRNA. Sci. Rep. 3, 2931; DOI:10.1038/srep02931 (2013).